📊 Top 10 Pharma by Market Cap in 2026 👇
As we enter 2026, let’s remind ourselves who the largest pharma players are and what the rationale is behind their valuation.
🚀 Eli Lilly and Company is THE largest pharma with the highest market cap (+38% in 2025) because of its obesity/diabetes medicines growth, together with their rapid manufacturing expansion that converts demand into revenue. It also became in 2025 the 1st pharma company ever to be valued at +$1000B.
🛡️ Johnson & Johnson is mostly valued for its resilience with diversified cash flows across innovative pharma and medtech and a strong balance sheet. Stronger-than-expected operational results led to a fantastic +43% in 2025 for J&J.
🔄 AbbVie is highly valued based on investors' confidence in the post-Humira era (+27% in 2025): Skyrizi and Rinvoq are replacing lost Humira revenue faster than expected, supporting earnings durability.
🛡️ Roche similarly to J&J, is priced as a defensive compounder (+27% in 2025) pharma + diagnostics diversification, strong oncology heritage, and dividend reliability.
🔬 AstraZeneca has experienced a broad-based growth across oncology, CVRM, respiratory, and rare disease with ambitious long-term targets. A small discount on geopolitical/pricing risk and the challenge of sustaining high growth across many programs and regions. Solid + 30% for AZ.
🧩 Novartis is now 100% focused on innovative medicines after its portfolio simplification (spun off Sandoz), which led to a margin expansion and productivity narrative. + 23% for Novartis's stock in 2025.
🧱 Merck is valued for massive current cash flows led by Keytruda, strong vaccine presence, and a robust development engine. Key risk is the widely discussed Keytruda patent cliff, and uncertainty on their new launches and pipeline assets can replace that earnings base (shy +6% for Merck & Co in 2025)
📉 Novo Nordisk lost a lot of market cap (-48%) in 2025 because of disappointing next-gen obesity data (CagriSema) versus high expectations, intensifying competition with Eli Lilly + CEO transition uncertainty.
🔬 Amgen is the Big biotech among large pharmas with meaningful dividends/buybacks and a pipeline for renewed growth. Notably, their obesity candidate MariTide is a key upside lever. The market discounts the need for sustained late-stage wins. +26% in 2025.
🌱 Gilead Sciences is valued on durable HIV cash flows (Biktarvy-led franchise) + oncology/cell-therapy as the main growth re-acceleration path. Very solid +33% growth in 1 year for Gilead.